Transaction

Laprophan Group acquires majority stake in Rivopharm

Announced
25 June 2026
Target
Rivopharm SA
Value
Undisclosed
Asset class
Corporate Transactions
Type
Merger/Acquisition(M&A)
Instrument
Ordinary Shares (Equity)
Lead investors
Laprophan S.A
Investors
Laprophan S.A
Sector
Healthcare / Biotechnology, Pharmaceuticals

About the target

Rivopharm SA is a Switzerland-based pharmaceutical manufacturer specialising in generic medicines, specialty pharmaceutical formulations, dossier development, and value-added pharmaceutical solutions. Incorporated in 1961 and headquartered in Manno, Canton Ticino, the company develops and manufactures oral solid dosage forms, primarily tablets and capsules, and manages a proprietary portfolio of approximately 125 molecules and nearly 1,500 SKUs distributed across more than 30 countries. Rivopharm operates an FDA-, TGA-, Swissmedic- and EU-approved manufacturing facility in Manno and maintains subsidiaries in the United Kingdom, Germany, and Lithuania.

Sources

  1. www.mcapitalp.com
  2. Partner Researchers